1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

chimeric monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

5

Peptides

34

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9913
    Rituximab
    Maximum Cited Publications
    6 Publications Verification

    Anti-Human CD20 type I, chimeric antibody

    CD20 Inflammation/Immunology Cancer
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    Rituximab
  • HY-P9913A
    Rituximab (anti-CD20)
    Maximum Cited Publications
    6 Publications Verification

    CD20 Inflammation/Immunology Cancer
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
    Rituximab (anti-CD20)
  • HY-P99686

    c4G7-N

    Filovirus Infection
    Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
    Larcaviximab
  • HY-P99628

    EGFR Cancer
    Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
    Futuximab
  • HY-P3149

    TNF Receptor Inflammation/Immunology
    LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
    LEESGGGLVQPGGSMK
  • HY-P3149B

    TNF Receptor Inflammation/Immunology
    LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
    LEESGGGLVQPGGSMK acetate
  • HY-P3203A

    TNF Receptor Inflammation/Immunology
    DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
    DSTYSLSSTLTLSK TFA
  • HY-P99023

    G250; cG250

    Carbonic Anhydrase Cancer
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
    Girentuximab
  • HY-108852

    CHI 621

    Interleukin Related Inflammation/Immunology
    Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
    Basiliximab
  • HY-P3149A

    TNF Receptor Inflammation/Immunology
    LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
    LEESGGGLVQPGGSMK TFA
  • HY-P99832

    c13C6-FR1

    Filovirus Infection
    Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
    Cosfroviximab
  • HY-P990084

    IGF-1R Cancer
    Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .
    Veligrotug
  • HY-P99151

    TNF Receptor Cancer
    Brentuximab is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies .
    Brentuximab
  • HY-P99238

    Interleukin Related Inflammation/Immunology Cancer
    Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody. Rolinsatamab chimeric antigen receptor sequence T cell. Rolinsatamab can be used in research of immune disease .
    Rolinsatamab
  • HY-P99538

    LFB-R603; TG-1101; TGTX-1101

    CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-P99030

    EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
    Margetuximab
  • HY-P9934

    C7E3

    Integrin Cardiovascular Disease
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
    Abciximab
  • HY-P99530

    AGT-181; HIRMAb-IDUA

    Insulin Receptor Metabolic Disease
    Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .
    Valanafusp alfa
  • HY-P9970
    Infliximab
    Maximum Cited Publications
    6 Publications Verification

    Avakine; CT-P13

    TNF Receptor Bacterial Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab
  • HY-P99351

    Anti-MMP9 Reference antibody (andecaliximab)

    MMP Cancer
    Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
    Andecaliximab
  • HY-P99321

    BMS 224819; Chi220; Anti-Human CD40 Recombinant antibody

    TNF Receptor Inflammation/Immunology Cancer
    Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
    Teneliximab
  • HY-P99680

    SB-210396; IDEC CE9.1

    Interleukin Related Cancer
    Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
    Keliximab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: